nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—Melphalan—peripheral nervous system neoplasm	0.483	1	CrCtD
L-DOPA—SLC7A5—Melphalan—peripheral nervous system neoplasm	0.247	0.993	CbGbCtD
L-DOPA—L-Tyrosine—Melphalan—peripheral nervous system neoplasm	0.121	0.702	CrCrCtD
L-DOPA—L-Phenylalanine—Melphalan—peripheral nervous system neoplasm	0.0515	0.298	CrCrCtD
L-DOPA—CYP2D6—Doxorubicin—peripheral nervous system neoplasm	0.00176	0.00707	CbGbCtD
L-DOPA—SLC7A8—tongue—peripheral nervous system neoplasm	0.00105	0.1	CbGeAlD
L-DOPA—DDC—nerve—peripheral nervous system neoplasm	0.000929	0.0886	CbGeAlD
L-DOPA—DDC—ganglion—peripheral nervous system neoplasm	0.000917	0.0875	CbGeAlD
L-DOPA—DRD5—ganglion—peripheral nervous system neoplasm	0.000882	0.0841	CbGeAlD
L-DOPA—PSIP1—trigeminal ganglion—peripheral nervous system neoplasm	0.00079	0.0753	CbGeAlD
L-DOPA—L-Tyrosine—TH—peripheral nervous system neoplasm	0.000742	0.589	CrCbGaD
L-DOPA—PSIP1—brainstem—peripheral nervous system neoplasm	0.000699	0.0667	CbGeAlD
L-DOPA—DRD1—nerve—peripheral nervous system neoplasm	0.000683	0.0651	CbGeAlD
L-DOPA—DRD1—ganglion—peripheral nervous system neoplasm	0.000674	0.0643	CbGeAlD
L-DOPA—L-Phenylalanine—TH—peripheral nervous system neoplasm	0.00043	0.342	CrCbGaD
L-DOPA—SLC7A5—trigeminal ganglion—peripheral nervous system neoplasm	0.000404	0.0385	CbGeAlD
L-DOPA—DRD2—nerve—peripheral nervous system neoplasm	0.000403	0.0384	CbGeAlD
L-DOPA—DDC—brainstem—peripheral nervous system neoplasm	0.000399	0.038	CbGeAlD
L-DOPA—DRD2—ganglion—peripheral nervous system neoplasm	0.000398	0.038	CbGeAlD
L-DOPA—SLC7A5—parotid gland—peripheral nervous system neoplasm	0.000381	0.0363	CbGeAlD
L-DOPA—PSIP1—cerebellum—peripheral nervous system neoplasm	0.000345	0.0329	CbGeAlD
L-DOPA—DRD1—brainstem—peripheral nervous system neoplasm	0.000293	0.0279	CbGeAlD
L-DOPA—SLC16A10—parotid gland—peripheral nervous system neoplasm	0.000291	0.0278	CbGeAlD
L-DOPA—SLC7A5—Isotretinoin—Tretinoin—peripheral nervous system neoplasm	0.00028	0.127	CbGdCrCtD
L-DOPA—SLC7A5—Tretinoin—Isotretinoin—peripheral nervous system neoplasm	0.00028	0.127	CbGdCrCtD
L-DOPA—SLC7A5—Alitretinoin—Isotretinoin—peripheral nervous system neoplasm	0.00028	0.127	CbGdCrCtD
L-DOPA—SLC7A5—Alitretinoin—Tretinoin—peripheral nervous system neoplasm	0.00028	0.127	CbGdCrCtD
L-DOPA—PSIP1—Teniposide—Etoposide—peripheral nervous system neoplasm	0.000249	0.112	CbGdCrCtD
L-DOPA—PSIP1—Podofilox—Etoposide—peripheral nervous system neoplasm	0.000249	0.112	CbGdCrCtD
L-DOPA—SLC7A8—cerebellum—peripheral nervous system neoplasm	0.000227	0.0217	CbGeAlD
L-DOPA—SLC7A5—Tretinoin—Alitretinoin—peripheral nervous system neoplasm	0.000212	0.0959	CbGdCrCtD
L-DOPA—SLC7A5—Isotretinoin—Alitretinoin—peripheral nervous system neoplasm	0.000212	0.0959	CbGdCrCtD
L-DOPA—SLC7A5—cerebellum—peripheral nervous system neoplasm	0.000176	0.0168	CbGeAlD
L-DOPA—DRD2—brainstem—peripheral nervous system neoplasm	0.000173	0.0165	CbGeAlD
L-DOPA—PSIP1—Vinblastine—Vincristine—peripheral nervous system neoplasm	0.000171	0.0774	CbGdCrCtD
L-DOPA—SLC16A10—cerebellum—peripheral nervous system neoplasm	0.000135	0.0129	CbGeAlD
L-DOPA—CYP2D6—brainstem—peripheral nervous system neoplasm	0.000104	0.00992	CbGeAlD
L-DOPA—Liothyronine—ABCB1—peripheral nervous system neoplasm	8.75e-05	0.0695	CrCbGaD
L-DOPA—DRD2—cerebellum—peripheral nervous system neoplasm	8.53e-05	0.00814	CbGeAlD
L-DOPA—CYP2D6—cerebellum—peripheral nervous system neoplasm	5.13e-05	0.00489	CbGeAlD
L-DOPA—Rash—Isotretinoin—peripheral nervous system neoplasm	5.04e-05	0.000762	CcSEcCtD
L-DOPA—Rash—Tretinoin—peripheral nervous system neoplasm	5.04e-05	0.000762	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	5.04e-05	0.000762	CcSEcCtD
L-DOPA—Dermatitis—Tretinoin—peripheral nervous system neoplasm	5.04e-05	0.000761	CcSEcCtD
L-DOPA—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	5.04e-05	0.000761	CcSEcCtD
L-DOPA—Fatigue—Vincristine—peripheral nervous system neoplasm	5.04e-05	0.000761	CcSEcCtD
L-DOPA—Convulsion—Etoposide—peripheral nervous system neoplasm	5.02e-05	0.000759	CcSEcCtD
L-DOPA—Vomiting—Melphalan—peripheral nervous system neoplasm	5.02e-05	0.000758	CcSEcCtD
L-DOPA—Headache—Isotretinoin—peripheral nervous system neoplasm	5.01e-05	0.000757	CcSEcCtD
L-DOPA—Headache—Tretinoin—peripheral nervous system neoplasm	5.01e-05	0.000757	CcSEcCtD
L-DOPA—Hypertension—Etoposide—peripheral nervous system neoplasm	5.01e-05	0.000756	CcSEcCtD
L-DOPA—Feeling abnormal—Alitretinoin—peripheral nervous system neoplasm	5e-05	0.000755	CcSEcCtD
L-DOPA—Constipation—Vincristine—peripheral nervous system neoplasm	5e-05	0.000755	CcSEcCtD
L-DOPA—Pain—Vincristine—peripheral nervous system neoplasm	5e-05	0.000755	CcSEcCtD
L-DOPA—Gastrointestinal haemorrhage—Doxorubicin—peripheral nervous system neoplasm	4.99e-05	0.000754	CcSEcCtD
L-DOPA—Diplopia—Doxorubicin—peripheral nervous system neoplasm	4.99e-05	0.000754	CcSEcCtD
L-DOPA—Pain in extremity—Doxorubicin—peripheral nervous system neoplasm	4.99e-05	0.000754	CcSEcCtD
L-DOPA—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	4.99e-05	0.000754	CcSEcCtD
L-DOPA—Rash—Melphalan—peripheral nervous system neoplasm	4.98e-05	0.000752	CcSEcCtD
L-DOPA—Dermatitis—Melphalan—peripheral nervous system neoplasm	4.97e-05	0.000751	CcSEcCtD
L-DOPA—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	4.96e-05	0.000749	CcSEcCtD
L-DOPA—Chest pain—Etoposide—peripheral nervous system neoplasm	4.94e-05	0.000746	CcSEcCtD
L-DOPA—Orthostatic hypotension—Epirubicin—peripheral nervous system neoplasm	4.93e-05	0.000745	CcSEcCtD
L-DOPA—Anorexia—Cisplatin—peripheral nervous system neoplasm	4.92e-05	0.000744	CcSEcCtD
L-DOPA—Discomfort—Etoposide—peripheral nervous system neoplasm	4.88e-05	0.000737	CcSEcCtD
L-DOPA—Hypotension—Cisplatin—peripheral nervous system neoplasm	4.83e-05	0.000729	CcSEcCtD
L-DOPA—Nasopharyngitis—Epirubicin—peripheral nervous system neoplasm	4.83e-05	0.000729	CcSEcCtD
L-DOPA—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	4.82e-05	0.000728	CcSEcCtD
L-DOPA—Urticaria—Alitretinoin—peripheral nervous system neoplasm	4.82e-05	0.000728	CcSEcCtD
L-DOPA—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	4.79e-05	0.000724	CcSEcCtD
L-DOPA—Nausea—Topotecan—peripheral nervous system neoplasm	4.79e-05	0.000724	CcSEcCtD
L-DOPA—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	4.78e-05	0.000722	CcSEcCtD
L-DOPA—Gastritis—Epirubicin—peripheral nervous system neoplasm	4.78e-05	0.000722	CcSEcCtD
L-DOPA—Confusional state—Etoposide—peripheral nervous system neoplasm	4.77e-05	0.000721	CcSEcCtD
L-DOPA—Nausea—Isotretinoin—peripheral nervous system neoplasm	4.75e-05	0.000718	CcSEcCtD
L-DOPA—Nausea—Tretinoin—peripheral nervous system neoplasm	4.75e-05	0.000718	CcSEcCtD
L-DOPA—Ataxia—Doxorubicin—peripheral nervous system neoplasm	4.7e-05	0.000709	CcSEcCtD
L-DOPA—Asthenia—Dactinomycin—peripheral nervous system neoplasm	4.69e-05	0.000709	CcSEcCtD
L-DOPA—Nausea—Melphalan—peripheral nervous system neoplasm	4.69e-05	0.000708	CcSEcCtD
L-DOPA—Blood creatinine increased—Doxorubicin—peripheral nervous system neoplasm	4.68e-05	0.000707	CcSEcCtD
L-DOPA—Dysphagia—Epirubicin—peripheral nervous system neoplasm	4.66e-05	0.000705	CcSEcCtD
L-DOPA—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	4.64e-05	0.000701	CcSEcCtD
L-DOPA—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	4.63e-05	0.0007	CcSEcCtD
L-DOPA—Abdominal pain—Vincristine—peripheral nervous system neoplasm	4.62e-05	0.000698	CcSEcCtD
L-DOPA—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	4.6e-05	0.000696	CcSEcCtD
L-DOPA—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	4.57e-05	0.000691	CcSEcCtD
L-DOPA—Orthostatic hypotension—Doxorubicin—peripheral nervous system neoplasm	4.56e-05	0.000689	CcSEcCtD
L-DOPA—Angina pectoris—Epirubicin—peripheral nervous system neoplasm	4.54e-05	0.000686	CcSEcCtD
L-DOPA—Anorexia—Etoposide—peripheral nervous system neoplasm	4.51e-05	0.000681	CcSEcCtD
L-DOPA—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	4.49e-05	0.000678	CcSEcCtD
L-DOPA—DRD4—Circadian rythm related genes—TH—peripheral nervous system neoplasm	4.48e-05	0.00291	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—NTS—peripheral nervous system neoplasm	4.48e-05	0.00291	CbGpPWpGaD
L-DOPA—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	4.47e-05	0.000676	CcSEcCtD
L-DOPA—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	4.47e-05	0.000675	CcSEcCtD
L-DOPA—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	4.47e-05	0.000675	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	4.46e-05	0.000674	CcSEcCtD
L-DOPA—PSIP1—Disease—SLC2A1—peripheral nervous system neoplasm	4.45e-05	0.00289	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	4.44e-05	0.00288	CbGpPWpGaD
L-DOPA—Hypotension—Etoposide—peripheral nervous system neoplasm	4.42e-05	0.000668	CcSEcCtD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	4.42e-05	0.00287	CbGpPWpGaD
L-DOPA—Gastritis—Doxorubicin—peripheral nervous system neoplasm	4.42e-05	0.000668	CcSEcCtD
L-DOPA—Pain—Cisplatin—peripheral nervous system neoplasm	4.42e-05	0.000667	CcSEcCtD
L-DOPA—DRD3—GPCR ligand binding—NTS—peripheral nervous system neoplasm	4.42e-05	0.00287	CbGpPWpGaD
L-DOPA—Asthenia—Alitretinoin—peripheral nervous system neoplasm	4.35e-05	0.000657	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	4.33e-05	0.000655	CcSEcCtD
L-DOPA—Dysphagia—Doxorubicin—peripheral nervous system neoplasm	4.32e-05	0.000652	CcSEcCtD
L-DOPA—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	4.31e-05	0.000651	CcSEcCtD
L-DOPA—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	4.3e-05	0.00065	CcSEcCtD
L-DOPA—DDC—Metabolism—HSD17B12—peripheral nervous system neoplasm	4.3e-05	0.00279	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—CD55—peripheral nervous system neoplasm	4.29e-05	0.00279	CbGpPWpGaD
L-DOPA—Pruritus—Alitretinoin—peripheral nervous system neoplasm	4.29e-05	0.000648	CcSEcCtD
L-DOPA—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	4.26e-05	0.000643	CcSEcCtD
L-DOPA—Paraesthesia—Etoposide—peripheral nervous system neoplasm	4.25e-05	0.000642	CcSEcCtD
L-DOPA—Weight increased—Epirubicin—peripheral nervous system neoplasm	4.24e-05	0.000641	CcSEcCtD
L-DOPA—DRD3—GPCR ligand binding—CD55—peripheral nervous system neoplasm	4.23e-05	0.00275	CbGpPWpGaD
L-DOPA—Weight decreased—Epirubicin—peripheral nervous system neoplasm	4.22e-05	0.000638	CcSEcCtD
L-DOPA—Dyspnoea—Etoposide—peripheral nervous system neoplasm	4.22e-05	0.000637	CcSEcCtD
L-DOPA—SLC7A5—Hemostasis—GNAS—peripheral nervous system neoplasm	4.21e-05	0.00274	CbGpPWpGaD
L-DOPA—Somnolence—Etoposide—peripheral nervous system neoplasm	4.21e-05	0.000636	CcSEcCtD
L-DOPA—Angina pectoris—Doxorubicin—peripheral nervous system neoplasm	4.2e-05	0.000635	CcSEcCtD
L-DOPA—Asthenia—Vincristine—peripheral nervous system neoplasm	4.19e-05	0.000633	CcSEcCtD
L-DOPA—SLC7A8—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	4.18e-05	0.00271	CbGpPWpGaD
L-DOPA—Vomiting—Dactinomycin—peripheral nervous system neoplasm	4.16e-05	0.000628	CcSEcCtD
L-DOPA—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	4.15e-05	0.000627	CcSEcCtD
L-DOPA—Rash—Dactinomycin—peripheral nervous system neoplasm	4.12e-05	0.000623	CcSEcCtD
L-DOPA—Decreased appetite—Etoposide—peripheral nervous system neoplasm	4.11e-05	0.000621	CcSEcCtD
L-DOPA—SLC7A8—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	4.1e-05	0.00266	CbGpPWpGaD
L-DOPA—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	4.09e-05	0.000617	CcSEcCtD
L-DOPA—Fatigue—Etoposide—peripheral nervous system neoplasm	4.08e-05	0.000616	CcSEcCtD
L-DOPA—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	4.08e-05	0.000616	CcSEcCtD
L-DOPA—Constipation—Etoposide—peripheral nervous system neoplasm	4.05e-05	0.000611	CcSEcCtD
L-DOPA—Pain—Etoposide—peripheral nervous system neoplasm	4.05e-05	0.000611	CcSEcCtD
L-DOPA—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	4.04e-05	0.000611	CcSEcCtD
L-DOPA—DRD1—Circadian rythm related genes—TH—peripheral nervous system neoplasm	4.03e-05	0.00262	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—HGF—peripheral nervous system neoplasm	4.01e-05	0.00261	CbGpPWpGaD
L-DOPA—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	4.01e-05	0.000606	CcSEcCtD
L-DOPA—Dizziness—Alitretinoin—peripheral nervous system neoplasm	4.01e-05	0.000606	CcSEcCtD
L-DOPA—Diarrhoea—Vincristine—peripheral nervous system neoplasm	4e-05	0.000604	CcSEcCtD
L-DOPA—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	3.99e-05	0.000602	CcSEcCtD
L-DOPA—DRD4—Circadian rythm related genes—NTRK1—peripheral nervous system neoplasm	3.98e-05	0.00259	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—TH—peripheral nervous system neoplasm	3.98e-05	0.00258	CbGpPWpGaD
L-DOPA—DRD5—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	3.98e-05	0.00258	CbGpPWpGaD
L-DOPA—Weight increased—Doxorubicin—peripheral nervous system neoplasm	3.93e-05	0.000593	CcSEcCtD
L-DOPA—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	3.9e-05	0.00059	CcSEcCtD
L-DOPA—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	3.9e-05	0.000589	CcSEcCtD
L-DOPA—Nausea—Dactinomycin—peripheral nervous system neoplasm	3.88e-05	0.000587	CcSEcCtD
L-DOPA—Agranulocytosis—Epirubicin—peripheral nervous system neoplasm	3.88e-05	0.000586	CcSEcCtD
L-DOPA—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	3.87e-05	0.000585	CcSEcCtD
L-DOPA—Dizziness—Vincristine—peripheral nervous system neoplasm	3.86e-05	0.000584	CcSEcCtD
L-DOPA—Vomiting—Alitretinoin—peripheral nervous system neoplasm	3.85e-05	0.000582	CcSEcCtD
L-DOPA—DDC—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	3.85e-05	0.0025	CbGpPWpGaD
L-DOPA—Rash—Alitretinoin—peripheral nervous system neoplasm	3.82e-05	0.000577	CcSEcCtD
L-DOPA—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	3.82e-05	0.000577	CcSEcCtD
L-DOPA—DRD5—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	3.81e-05	0.00247	CbGpPWpGaD
L-DOPA—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	3.81e-05	0.000575	CcSEcCtD
L-DOPA—Headache—Alitretinoin—peripheral nervous system neoplasm	3.8e-05	0.000574	CcSEcCtD
L-DOPA—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	3.77e-05	0.00057	CcSEcCtD
L-DOPA—Urticaria—Etoposide—peripheral nervous system neoplasm	3.76e-05	0.000568	CcSEcCtD
L-DOPA—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	3.75e-05	0.000567	CcSEcCtD
L-DOPA—Rhinitis—Epirubicin—peripheral nervous system neoplasm	3.74e-05	0.000565	CcSEcCtD
L-DOPA—Abdominal pain—Etoposide—peripheral nervous system neoplasm	3.74e-05	0.000565	CcSEcCtD
L-DOPA—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	3.74e-05	0.000565	CcSEcCtD
L-DOPA—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	3.73e-05	0.000564	CcSEcCtD
L-DOPA—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	3.71e-05	0.000561	CcSEcCtD
L-DOPA—Vomiting—Vincristine—peripheral nervous system neoplasm	3.71e-05	0.000561	CcSEcCtD
L-DOPA—Asthenia—Cisplatin—peripheral nervous system neoplasm	3.71e-05	0.00056	CcSEcCtD
L-DOPA—DRD4—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	3.69e-05	0.0024	CbGpPWpGaD
L-DOPA—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	3.69e-05	0.000557	CcSEcCtD
L-DOPA—Rash—Vincristine—peripheral nervous system neoplasm	3.68e-05	0.000556	CcSEcCtD
L-DOPA—Dermatitis—Vincristine—peripheral nervous system neoplasm	3.68e-05	0.000556	CcSEcCtD
L-DOPA—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	3.66e-05	0.000553	CcSEcCtD
L-DOPA—Headache—Vincristine—peripheral nervous system neoplasm	3.66e-05	0.000553	CcSEcCtD
L-DOPA—SLC7A5—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	3.65e-05	0.00237	CbGpPWpGaD
L-DOPA—Nausea—Alitretinoin—peripheral nervous system neoplasm	3.6e-05	0.000544	CcSEcCtD
L-DOPA—Agranulocytosis—Doxorubicin—peripheral nervous system neoplasm	3.59e-05	0.000543	CcSEcCtD
L-DOPA—DRD1—Circadian rythm related genes—NTRK1—peripheral nervous system neoplasm	3.59e-05	0.00233	CbGpPWpGaD
L-DOPA—SLC7A5—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	3.58e-05	0.00232	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—NTRK1—peripheral nervous system neoplasm	3.54e-05	0.0023	CbGpPWpGaD
L-DOPA—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	3.53e-05	0.000534	CcSEcCtD
L-DOPA—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	3.49e-05	0.000527	CcSEcCtD
L-DOPA—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	3.47e-05	0.000525	CcSEcCtD
L-DOPA—Nausea—Vincristine—peripheral nervous system neoplasm	3.47e-05	0.000524	CcSEcCtD
L-DOPA—Flushing—Epirubicin—peripheral nervous system neoplasm	3.46e-05	0.000523	CcSEcCtD
L-DOPA—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	3.46e-05	0.000523	CcSEcCtD
L-DOPA—DRD5—Signaling by GPCR—NTS—peripheral nervous system neoplasm	3.46e-05	0.00225	CbGpPWpGaD
L-DOPA—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	3.45e-05	0.000522	CcSEcCtD
L-DOPA—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	3.44e-05	0.000519	CcSEcCtD
L-DOPA—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	3.41e-05	0.000515	CcSEcCtD
L-DOPA—Asthenia—Etoposide—peripheral nervous system neoplasm	3.39e-05	0.000513	CcSEcCtD
L-DOPA—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	3.39e-05	0.000512	CcSEcCtD
L-DOPA—DRD2—GPCR ligand binding—NTS—peripheral nervous system neoplasm	3.38e-05	0.0022	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—PTPN11—peripheral nervous system neoplasm	3.35e-05	0.00218	CbGpPWpGaD
L-DOPA—Pruritus—Etoposide—peripheral nervous system neoplasm	3.35e-05	0.000506	CcSEcCtD
L-DOPA—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	3.34e-05	0.000504	CcSEcCtD
L-DOPA—DRD5—Signaling by GPCR—CD55—peripheral nervous system neoplasm	3.31e-05	0.00215	CbGpPWpGaD
L-DOPA—Alopecia—Epirubicin—peripheral nervous system neoplasm	3.3e-05	0.000498	CcSEcCtD
L-DOPA—Vomiting—Cisplatin—peripheral nervous system neoplasm	3.28e-05	0.000496	CcSEcCtD
L-DOPA—DRD3—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	3.28e-05	0.00213	CbGpPWpGaD
L-DOPA—Mental disorder—Epirubicin—peripheral nervous system neoplasm	3.27e-05	0.000494	CcSEcCtD
L-DOPA—Rash—Cisplatin—peripheral nervous system neoplasm	3.26e-05	0.000492	CcSEcCtD
L-DOPA—Dermatitis—Cisplatin—peripheral nervous system neoplasm	3.25e-05	0.000492	CcSEcCtD
L-DOPA—DRD2—GPCR ligand binding—CD55—peripheral nervous system neoplasm	3.24e-05	0.0021	CbGpPWpGaD
L-DOPA—Diarrhoea—Etoposide—peripheral nervous system neoplasm	3.24e-05	0.000489	CcSEcCtD
L-DOPA—DRD4—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	3.23e-05	0.0021	CbGpPWpGaD
L-DOPA—Flushing—Doxorubicin—peripheral nervous system neoplasm	3.21e-05	0.000484	CcSEcCtD
L-DOPA—Flatulence—Epirubicin—peripheral nervous system neoplasm	3.2e-05	0.000484	CcSEcCtD
L-DOPA—Tension—Epirubicin—peripheral nervous system neoplasm	3.19e-05	0.000482	CcSEcCtD
L-DOPA—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	3.18e-05	0.000481	CcSEcCtD
L-DOPA—Nervousness—Epirubicin—peripheral nervous system neoplasm	3.16e-05	0.000477	CcSEcCtD
L-DOPA—Back pain—Epirubicin—peripheral nervous system neoplasm	3.14e-05	0.000475	CcSEcCtD
L-DOPA—Dizziness—Etoposide—peripheral nervous system neoplasm	3.13e-05	0.000473	CcSEcCtD
L-DOPA—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	3.12e-05	0.000472	CcSEcCtD
L-DOPA—DDC—Metabolism—GNS—peripheral nervous system neoplasm	3.11e-05	0.00202	CbGpPWpGaD
L-DOPA—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	3.09e-05	0.000466	CcSEcCtD
L-DOPA—Nausea—Cisplatin—peripheral nervous system neoplasm	3.07e-05	0.000463	CcSEcCtD
L-DOPA—Vision blurred—Epirubicin—peripheral nervous system neoplasm	3.06e-05	0.000463	CcSEcCtD
L-DOPA—Alopecia—Doxorubicin—peripheral nervous system neoplasm	3.05e-05	0.000461	CcSEcCtD
L-DOPA—DRD2—Circadian rythm related genes—TH—peripheral nervous system neoplasm	3.04e-05	0.00198	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	3.03e-05	0.00197	CbGpPWpGaD
L-DOPA—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	3.03e-05	0.000457	CcSEcCtD
L-DOPA—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	3.02e-05	0.000456	CcSEcCtD
L-DOPA—SLC16A10—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	3.01e-05	0.00196	CbGpPWpGaD
L-DOPA—Vomiting—Etoposide—peripheral nervous system neoplasm	3.01e-05	0.000455	CcSEcCtD
L-DOPA—Anaemia—Epirubicin—peripheral nervous system neoplasm	3e-05	0.000454	CcSEcCtD
L-DOPA—Agitation—Epirubicin—peripheral nervous system neoplasm	2.99e-05	0.000451	CcSEcCtD
L-DOPA—Rash—Etoposide—peripheral nervous system neoplasm	2.98e-05	0.000451	CcSEcCtD
L-DOPA—Dermatitis—Etoposide—peripheral nervous system neoplasm	2.98e-05	0.00045	CcSEcCtD
L-DOPA—DDC—Metabolism—NME1—peripheral nervous system neoplasm	2.98e-05	0.00194	CbGpPWpGaD
L-DOPA—Headache—Etoposide—peripheral nervous system neoplasm	2.96e-05	0.000448	CcSEcCtD
L-DOPA—Flatulence—Doxorubicin—peripheral nervous system neoplasm	2.96e-05	0.000448	CcSEcCtD
L-DOPA—Tension—Doxorubicin—peripheral nervous system neoplasm	2.95e-05	0.000446	CcSEcCtD
L-DOPA—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	2.94e-05	0.000445	CcSEcCtD
L-DOPA—DRD4—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	2.93e-05	0.00191	CbGpPWpGaD
L-DOPA—Malaise—Epirubicin—peripheral nervous system neoplasm	2.93e-05	0.000443	CcSEcCtD
L-DOPA—SLC7A5—Hemostasis—PTPN11—peripheral nervous system neoplasm	2.93e-05	0.0019	CbGpPWpGaD
L-DOPA—Nervousness—Doxorubicin—peripheral nervous system neoplasm	2.92e-05	0.000441	CcSEcCtD
L-DOPA—Syncope—Epirubicin—peripheral nervous system neoplasm	2.91e-05	0.00044	CcSEcCtD
L-DOPA—Leukopenia—Epirubicin—peripheral nervous system neoplasm	2.91e-05	0.000439	CcSEcCtD
L-DOPA—Back pain—Doxorubicin—peripheral nervous system neoplasm	2.91e-05	0.000439	CcSEcCtD
L-DOPA—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	2.89e-05	0.000437	CcSEcCtD
L-DOPA—DRD5—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	2.89e-05	0.00187	CbGpPWpGaD
L-DOPA—Palpitations—Epirubicin—peripheral nervous system neoplasm	2.87e-05	0.000434	CcSEcCtD
L-DOPA—DDC—Metabolism—COX2—peripheral nervous system neoplasm	2.87e-05	0.00186	CbGpPWpGaD
L-DOPA—DRD3—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	2.87e-05	0.00186	CbGpPWpGaD
L-DOPA—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	2.86e-05	0.000432	CcSEcCtD
L-DOPA—Cough—Epirubicin—peripheral nervous system neoplasm	2.84e-05	0.000428	CcSEcCtD
L-DOPA—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	2.83e-05	0.000428	CcSEcCtD
L-DOPA—Convulsion—Epirubicin—peripheral nervous system neoplasm	2.82e-05	0.000425	CcSEcCtD
L-DOPA—Nausea—Etoposide—peripheral nervous system neoplasm	2.81e-05	0.000425	CcSEcCtD
L-DOPA—DRD4—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	2.81e-05	0.00183	CbGpPWpGaD
L-DOPA—Hypertension—Epirubicin—peripheral nervous system neoplasm	2.81e-05	0.000424	CcSEcCtD
L-DOPA—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	2.79e-05	0.000422	CcSEcCtD
L-DOPA—Anaemia—Doxorubicin—peripheral nervous system neoplasm	2.78e-05	0.00042	CcSEcCtD
L-DOPA—Chest pain—Epirubicin—peripheral nervous system neoplasm	2.77e-05	0.000418	CcSEcCtD
L-DOPA—Agitation—Doxorubicin—peripheral nervous system neoplasm	2.76e-05	0.000417	CcSEcCtD
L-DOPA—Anxiety—Epirubicin—peripheral nervous system neoplasm	2.76e-05	0.000417	CcSEcCtD
L-DOPA—Discomfort—Epirubicin—peripheral nervous system neoplasm	2.73e-05	0.000413	CcSEcCtD
L-DOPA—Malaise—Doxorubicin—peripheral nervous system neoplasm	2.71e-05	0.00041	CcSEcCtD
L-DOPA—DRD2—Circadian rythm related genes—NTRK1—peripheral nervous system neoplasm	2.71e-05	0.00176	CbGpPWpGaD
L-DOPA—Dry mouth—Epirubicin—peripheral nervous system neoplasm	2.71e-05	0.000409	CcSEcCtD
L-DOPA—Syncope—Doxorubicin—peripheral nervous system neoplasm	2.7e-05	0.000407	CcSEcCtD
L-DOPA—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	2.69e-05	0.000407	CcSEcCtD
L-DOPA—Confusional state—Epirubicin—peripheral nervous system neoplasm	2.67e-05	0.000404	CcSEcCtD
L-DOPA—Palpitations—Doxorubicin—peripheral nervous system neoplasm	2.66e-05	0.000401	CcSEcCtD
L-DOPA—Oedema—Epirubicin—peripheral nervous system neoplasm	2.65e-05	0.000401	CcSEcCtD
L-DOPA—DRD5—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	2.65e-05	0.00172	CbGpPWpGaD
L-DOPA—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	2.64e-05	0.000399	CcSEcCtD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	2.64e-05	0.00172	CbGpPWpGaD
L-DOPA—Cough—Doxorubicin—peripheral nervous system neoplasm	2.62e-05	0.000396	CcSEcCtD
L-DOPA—DRD5—Signaling by GPCR—VIP—peripheral nervous system neoplasm	2.62e-05	0.0017	CbGpPWpGaD
L-DOPA—Shock—Epirubicin—peripheral nervous system neoplasm	2.61e-05	0.000394	CcSEcCtD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	2.61e-05	0.00169	CbGpPWpGaD
L-DOPA—Convulsion—Doxorubicin—peripheral nervous system neoplasm	2.61e-05	0.000394	CcSEcCtD
L-DOPA—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	2.6e-05	0.000392	CcSEcCtD
L-DOPA—Hypertension—Doxorubicin—peripheral nervous system neoplasm	2.6e-05	0.000392	CcSEcCtD
L-DOPA—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	2.56e-05	0.000387	CcSEcCtD
L-DOPA—Chest pain—Doxorubicin—peripheral nervous system neoplasm	2.56e-05	0.000387	CcSEcCtD
L-DOPA—DRD4—Signaling by GPCR—NTS—peripheral nervous system neoplasm	2.55e-05	0.00166	CbGpPWpGaD
L-DOPA—Anxiety—Doxorubicin—peripheral nervous system neoplasm	2.55e-05	0.000385	CcSEcCtD
L-DOPA—DRD1—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	2.53e-05	0.00164	CbGpPWpGaD
L-DOPA—Discomfort—Doxorubicin—peripheral nervous system neoplasm	2.53e-05	0.000382	CcSEcCtD
L-DOPA—Anorexia—Epirubicin—peripheral nervous system neoplasm	2.53e-05	0.000382	CcSEcCtD
L-DOPA—DRD2—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	2.51e-05	0.00163	CbGpPWpGaD
L-DOPA—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	2.5e-05	0.000378	CcSEcCtD
L-DOPA—DRD3—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	2.5e-05	0.00162	CbGpPWpGaD
L-DOPA—PSIP1—Disease—PTPN11—peripheral nervous system neoplasm	2.49e-05	0.00162	CbGpPWpGaD
L-DOPA—Hypotension—Epirubicin—peripheral nervous system neoplasm	2.48e-05	0.000374	CcSEcCtD
L-DOPA—Confusional state—Doxorubicin—peripheral nervous system neoplasm	2.47e-05	0.000374	CcSEcCtD
L-DOPA—Oedema—Doxorubicin—peripheral nervous system neoplasm	2.45e-05	0.000371	CcSEcCtD
L-DOPA—DRD4—Signaling by GPCR—CD55—peripheral nervous system neoplasm	2.45e-05	0.00159	CbGpPWpGaD
L-DOPA—SLC16A10—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	2.42e-05	0.00157	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	2.42e-05	0.00157	CbGpPWpGaD
L-DOPA—Shock—Doxorubicin—peripheral nervous system neoplasm	2.41e-05	0.000365	CcSEcCtD
L-DOPA—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	2.4e-05	0.000363	CcSEcCtD
L-DOPA—Insomnia—Epirubicin—peripheral nervous system neoplasm	2.4e-05	0.000362	CcSEcCtD
L-DOPA—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	2.38e-05	0.00036	CcSEcCtD
L-DOPA—SLC16A10—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	2.38e-05	0.00154	CbGpPWpGaD
L-DOPA—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	2.37e-05	0.000358	CcSEcCtD
L-DOPA—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	2.36e-05	0.000357	CcSEcCtD
L-DOPA—Somnolence—Epirubicin—peripheral nervous system neoplasm	2.36e-05	0.000356	CcSEcCtD
L-DOPA—Anorexia—Doxorubicin—peripheral nervous system neoplasm	2.34e-05	0.000353	CcSEcCtD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	2.34e-05	0.00152	CbGpPWpGaD
L-DOPA—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	2.33e-05	0.000353	CcSEcCtD
L-DOPA—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	2.31e-05	0.000348	CcSEcCtD
L-DOPA—DRD1—Signaling by GPCR—NTS—peripheral nervous system neoplasm	2.3e-05	0.00149	CbGpPWpGaD
L-DOPA—Hypotension—Doxorubicin—peripheral nervous system neoplasm	2.29e-05	0.000346	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	2.29e-05	0.000346	CcSEcCtD
L-DOPA—Fatigue—Epirubicin—peripheral nervous system neoplasm	2.29e-05	0.000345	CcSEcCtD
L-DOPA—Constipation—Epirubicin—peripheral nervous system neoplasm	2.27e-05	0.000343	CcSEcCtD
L-DOPA—Pain—Epirubicin—peripheral nervous system neoplasm	2.27e-05	0.000343	CcSEcCtD
L-DOPA—DRD3—Signaling by GPCR—NTS—peripheral nervous system neoplasm	2.27e-05	0.00147	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	2.23e-05	0.00145	CbGpPWpGaD
L-DOPA—Insomnia—Doxorubicin—peripheral nervous system neoplasm	2.22e-05	0.000335	CcSEcCtD
L-DOPA—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	2.2e-05	0.000333	CcSEcCtD
L-DOPA—DRD1—Signaling by GPCR—CD55—peripheral nervous system neoplasm	2.2e-05	0.00143	CbGpPWpGaD
L-DOPA—DRD2—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	2.19e-05	0.00142	CbGpPWpGaD
L-DOPA—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	2.19e-05	0.000331	CcSEcCtD
L-DOPA—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	2.19e-05	0.00033	CcSEcCtD
L-DOPA—Somnolence—Doxorubicin—peripheral nervous system neoplasm	2.18e-05	0.00033	CcSEcCtD
L-DOPA—DRD3—Signaling by GPCR—CD55—peripheral nervous system neoplasm	2.17e-05	0.00141	CbGpPWpGaD
L-DOPA—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	2.17e-05	0.000328	CcSEcCtD
L-DOPA—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	2.16e-05	0.000326	CcSEcCtD
L-DOPA—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	2.13e-05	0.000322	CcSEcCtD
L-DOPA—DRD4—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	2.13e-05	0.00138	CbGpPWpGaD
L-DOPA—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	2.12e-05	0.00032	CcSEcCtD
L-DOPA—Fatigue—Doxorubicin—peripheral nervous system neoplasm	2.12e-05	0.00032	CcSEcCtD
L-DOPA—Urticaria—Epirubicin—peripheral nervous system neoplasm	2.11e-05	0.000318	CcSEcCtD
L-DOPA—Pain—Doxorubicin—peripheral nervous system neoplasm	2.1e-05	0.000317	CcSEcCtD
L-DOPA—Constipation—Doxorubicin—peripheral nervous system neoplasm	2.1e-05	0.000317	CcSEcCtD
L-DOPA—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	2.1e-05	0.000317	CcSEcCtD
L-DOPA—DRD5—Signaling Pathways—NTS—peripheral nervous system neoplasm	2.04e-05	0.00133	CbGpPWpGaD
L-DOPA—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	2.02e-05	0.000306	CcSEcCtD
L-DOPA—SLC7A8—Hemostasis—NRAS—peripheral nervous system neoplasm	2.02e-05	0.00131	CbGpPWpGaD
L-DOPA—DDC—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	2.02e-05	0.00131	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	2.01e-05	0.00131	CbGpPWpGaD
L-DOPA—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	2.01e-05	0.000303	CcSEcCtD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	1.99e-05	0.0013	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	1.98e-05	0.00129	CbGpPWpGaD
L-DOPA—PSIP1—Disease—ERBB2—peripheral nervous system neoplasm	1.97e-05	0.00128	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CD55—peripheral nervous system neoplasm	1.96e-05	0.00127	CbGpPWpGaD
L-DOPA—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	1.95e-05	0.000295	CcSEcCtD
L-DOPA—DRD4—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	1.95e-05	0.00127	CbGpPWpGaD
L-DOPA—Urticaria—Doxorubicin—peripheral nervous system neoplasm	1.95e-05	0.000295	CcSEcCtD
L-DOPA—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	1.94e-05	0.000293	CcSEcCtD
L-DOPA—DRD4—Signaling by GPCR—VIP—peripheral nervous system neoplasm	1.93e-05	0.00126	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	1.92e-05	0.00125	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	1.91e-05	0.00124	CbGpPWpGaD
L-DOPA—Asthenia—Epirubicin—peripheral nervous system neoplasm	1.9e-05	0.000288	CcSEcCtD
L-DOPA—DRD3—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	1.89e-05	0.00123	CbGpPWpGaD
L-DOPA—DDC—Metabolism—ENO2—peripheral nervous system neoplasm	1.88e-05	0.00122	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	1.88e-05	0.00122	CbGpPWpGaD
L-DOPA—Pruritus—Epirubicin—peripheral nervous system neoplasm	1.88e-05	0.000284	CcSEcCtD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	1.85e-05	0.0012	CbGpPWpGaD
L-DOPA—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	1.81e-05	0.000274	CcSEcCtD
L-DOPA—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	1.81e-05	0.000273	CcSEcCtD
L-DOPA—DRD4—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	1.78e-05	0.00116	CbGpPWpGaD
L-DOPA—Asthenia—Doxorubicin—peripheral nervous system neoplasm	1.76e-05	0.000266	CcSEcCtD
L-DOPA—SLC7A5—Hemostasis—NRAS—peripheral nervous system neoplasm	1.76e-05	0.00114	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	1.76e-05	0.00114	CbGpPWpGaD
L-DOPA—Dizziness—Epirubicin—peripheral nervous system neoplasm	1.75e-05	0.000265	CcSEcCtD
L-DOPA—DRD1—Signaling by GPCR—VIP—peripheral nervous system neoplasm	1.74e-05	0.00113	CbGpPWpGaD
L-DOPA—Pruritus—Doxorubicin—peripheral nervous system neoplasm	1.74e-05	0.000262	CcSEcCtD
L-DOPA—DRD3—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	1.74e-05	0.00113	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—NTS—peripheral nervous system neoplasm	1.73e-05	0.00113	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—VIP—peripheral nervous system neoplasm	1.72e-05	0.00112	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	1.71e-05	0.00111	CbGpPWpGaD
L-DOPA—Vomiting—Epirubicin—peripheral nervous system neoplasm	1.69e-05	0.000255	CcSEcCtD
L-DOPA—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	1.68e-05	0.000254	CcSEcCtD
L-DOPA—Rash—Epirubicin—peripheral nervous system neoplasm	1.67e-05	0.000253	CcSEcCtD
L-DOPA—Dermatitis—Epirubicin—peripheral nervous system neoplasm	1.67e-05	0.000252	CcSEcCtD
L-DOPA—DRD2—Signaling by GPCR—CD55—peripheral nervous system neoplasm	1.66e-05	0.00108	CbGpPWpGaD
L-DOPA—Headache—Epirubicin—peripheral nervous system neoplasm	1.66e-05	0.000251	CcSEcCtD
L-DOPA—Dizziness—Doxorubicin—peripheral nervous system neoplasm	1.62e-05	0.000245	CcSEcCtD
L-DOPA—DRD1—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	1.61e-05	0.00104	CbGpPWpGaD
L-DOPA—DDC—Metabolism—BCHE—peripheral nervous system neoplasm	1.59e-05	0.00103	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	1.59e-05	0.00103	CbGpPWpGaD
L-DOPA—Nausea—Epirubicin—peripheral nervous system neoplasm	1.58e-05	0.000238	CcSEcCtD
L-DOPA—Vomiting—Doxorubicin—peripheral nervous system neoplasm	1.56e-05	0.000236	CcSEcCtD
L-DOPA—DRD5—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	1.55e-05	0.00101	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—VIP—peripheral nervous system neoplasm	1.55e-05	0.00101	CbGpPWpGaD
L-DOPA—Rash—Doxorubicin—peripheral nervous system neoplasm	1.55e-05	0.000234	CcSEcCtD
L-DOPA—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	1.55e-05	0.000234	CcSEcCtD
L-DOPA—SLC7A8—Hemostasis—TP53—peripheral nervous system neoplasm	1.54e-05	0.001	CbGpPWpGaD
L-DOPA—Headache—Doxorubicin—peripheral nervous system neoplasm	1.54e-05	0.000232	CcSEcCtD
L-DOPA—DRD2—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	1.52e-05	0.000987	CbGpPWpGaD
L-DOPA—DDC—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.52e-05	0.000986	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NTS—peripheral nervous system neoplasm	1.51e-05	0.000979	CbGpPWpGaD
L-DOPA—PSIP1—Disease—NRAS—peripheral nervous system neoplasm	1.5e-05	0.000972	CbGpPWpGaD
L-DOPA—DDC—Metabolism—TH—peripheral nervous system neoplasm	1.5e-05	0.000972	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	1.5e-05	0.000972	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—HRAS—peripheral nervous system neoplasm	1.48e-05	0.000959	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PPIP5K2—peripheral nervous system neoplasm	1.46e-05	0.000951	CbGpPWpGaD
L-DOPA—Nausea—Doxorubicin—peripheral nervous system neoplasm	1.46e-05	0.00022	CcSEcCtD
L-DOPA—DRD2—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	1.45e-05	0.00094	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CD55—peripheral nervous system neoplasm	1.45e-05	0.000939	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.43e-05	0.000928	CbGpPWpGaD
L-DOPA—PSIP1—Disease—MYC—peripheral nervous system neoplasm	1.39e-05	0.000906	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.36e-05	0.000883	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NTS—peripheral nervous system neoplasm	1.36e-05	0.000882	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—TP53—peripheral nervous system neoplasm	1.35e-05	0.000875	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NTS—peripheral nervous system neoplasm	1.34e-05	0.00087	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	1.33e-05	0.000863	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—VIP—peripheral nervous system neoplasm	1.31e-05	0.000854	CbGpPWpGaD
L-DOPA—SLC7A8—Hemostasis—AKT1—peripheral nervous system neoplasm	1.3e-05	0.000846	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CD55—peripheral nervous system neoplasm	1.3e-05	0.000845	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—HRAS—peripheral nervous system neoplasm	1.29e-05	0.000836	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CD55—peripheral nervous system neoplasm	1.28e-05	0.000834	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	1.26e-05	0.00082	CbGpPWpGaD
L-DOPA—DDC—Metabolism—GNAS—peripheral nervous system neoplasm	1.22e-05	0.000793	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	1.21e-05	0.000788	CbGpPWpGaD
L-DOPA—DDC—Metabolism—ABCB1—peripheral nervous system neoplasm	1.2e-05	0.000779	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	1.17e-05	0.000759	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	1.15e-05	0.000745	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—VIP—peripheral nervous system neoplasm	1.14e-05	0.000742	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—AKT1—peripheral nervous system neoplasm	1.14e-05	0.000738	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	1.14e-05	0.000738	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	1.12e-05	0.000729	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	1.1e-05	0.000717	CbGpPWpGaD
L-DOPA—PSIP1—Disease—HRAS—peripheral nervous system neoplasm	1.09e-05	0.000711	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.07e-05	0.000697	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.05e-05	0.000685	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	1.05e-05	0.000684	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	1.04e-05	0.000674	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	1.03e-05	0.000671	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—VIP—peripheral nervous system neoplasm	1.03e-05	0.000668	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NTS—peripheral nervous system neoplasm	1.02e-05	0.000666	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	1.02e-05	0.000662	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—VIP—peripheral nervous system neoplasm	1.01e-05	0.000659	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1e-05	0.000651	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	9.94e-06	0.000646	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—HSD17B12—peripheral nervous system neoplasm	9.89e-06	0.000642	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CD55—peripheral nervous system neoplasm	9.82e-06	0.000638	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	9.81e-06	0.000637	CbGpPWpGaD
L-DOPA—PSIP1—Disease—AKT1—peripheral nervous system neoplasm	9.67e-06	0.000628	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	9.49e-06	0.000617	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	9.44e-06	0.000613	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	9.36e-06	0.000608	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—KNG1—peripheral nervous system neoplasm	9.18e-06	0.000596	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	9.03e-06	0.000586	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	8.91e-06	0.000579	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	8.75e-06	0.000568	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	8.58e-06	0.000558	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—GNAS—peripheral nervous system neoplasm	8.02e-06	0.000521	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	7.94e-06	0.000516	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	7.92e-06	0.000514	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	7.79e-06	0.000506	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—VIP—peripheral nervous system neoplasm	7.76e-06	0.000504	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	7.5e-06	0.000488	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	7.17e-06	0.000466	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GNS—peripheral nervous system neoplasm	7.15e-06	0.000464	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	7.13e-06	0.000463	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	7.03e-06	0.000457	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	6.97e-06	0.000453	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—NME1—peripheral nervous system neoplasm	6.85e-06	0.000445	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	6.81e-06	0.000443	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—KNG1—peripheral nervous system neoplasm	6.77e-06	0.00044	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—COX2—peripheral nervous system neoplasm	6.6e-06	0.000429	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	6.45e-06	0.000419	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	6.27e-06	0.000407	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	6.19e-06	0.000402	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	6.1e-06	0.000396	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—KNG1—peripheral nervous system neoplasm	6.02e-06	0.000391	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—GNAS—peripheral nervous system neoplasm	5.92e-06	0.000385	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	5.81e-06	0.000378	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	5.73e-06	0.000372	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	5.68e-06	0.000369	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	5.58e-06	0.000362	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	5.38e-06	0.00035	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	5.33e-06	0.000346	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—GNAS—peripheral nervous system neoplasm	5.26e-06	0.000342	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	4.74e-06	0.000308	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KNG1—peripheral nervous system neoplasm	4.6e-06	0.000299	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.41e-06	0.000286	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	4.39e-06	0.000285	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ENO2—peripheral nervous system neoplasm	4.33e-06	0.000281	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	4.19e-06	0.000272	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.15e-06	0.00027	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	4.12e-06	0.000267	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	4.04e-06	0.000262	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—GNAS—peripheral nervous system neoplasm	4.03e-06	0.000262	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4e-06	0.00026	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	3.77e-06	0.000245	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	3.72e-06	0.000242	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.71e-06	0.000241	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	3.67e-06	0.000238	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—BCHE—peripheral nervous system neoplasm	3.66e-06	0.000238	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.66e-06	0.000238	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.49e-06	0.000227	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—TH—peripheral nervous system neoplasm	3.44e-06	0.000223	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.35e-06	0.000218	CbGpPWpGaD
L-DOPA—DDC—Metabolism—AKT1—peripheral nervous system neoplasm	3.3e-06	0.000214	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.25e-06	0.000211	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.12e-06	0.000203	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	3.06e-06	0.000199	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.98e-06	0.000194	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.95e-06	0.000192	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.93e-06	0.00019	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.89e-06	0.000188	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.85e-06	0.000185	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GNAS—peripheral nervous system neoplasm	2.81e-06	0.000182	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.8e-06	0.000182	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.76e-06	0.000179	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ABCB1—peripheral nervous system neoplasm	2.76e-06	0.000179	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.72e-06	0.000177	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.71e-06	0.000176	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.68e-06	0.000174	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.66e-06	0.000173	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.65e-06	0.000172	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.62e-06	0.00017	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.57e-06	0.000167	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.47e-06	0.000161	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.45e-06	0.000159	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.44e-06	0.000158	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.4e-06	0.000156	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.31e-06	0.00015	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.23e-06	0.000145	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.21e-06	0.000144	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.2e-06	0.000143	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.17e-06	0.000141	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.08e-06	0.000135	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.08e-06	0.000135	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.05e-06	0.000133	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.03e-06	0.000132	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.01e-06	0.00013	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.89e-06	0.000123	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.84e-06	0.000119	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.81e-06	0.000118	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.7e-06	0.000111	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.68e-06	0.000109	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.68e-06	0.000109	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.63e-06	0.000106	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.61e-06	0.000104	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.6e-06	0.000104	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.57e-06	0.000102	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.44e-06	9.35e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.42e-06	9.23e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.29e-06	8.36e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.23e-06	7.99e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.09e-06	7.06e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—AKT1—peripheral nervous system neoplasm	7.58e-07	4.92e-05	CbGpPWpGaD
